New antibody drug takes on Hard-to-Treat cancers
NCT ID NCT04374877
First seen Nov 10, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight cancer. The study looked at safety, side effects, and whether the drug alone or combined with another immunotherapy (pembrolizumab) could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York, 10029, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
National Cancer Center Singapore (NCCS)
Singapore, 169610, Singapore
-
National University Hospital
Singapore, 119228, Singapore
-
Roswell Park
Buffalo, New York, 14263, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
University of Miami Leonard M. Miller School of Medicine (UMMSM)
Miami, Florida, 33136, United States
-
University of Michigan Health System (UMHS)
Ann Arbor, Michigan, 48109, United States
-
University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI))
Pittsburgh, Pennsylvania, 15232, United States
-
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Vanderbilt University Medical Center (VUMC)
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine - St. Louis
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.